Developing new medicines for Peyronie’s disease (v1)
Research type
Research Study
Full title
Developing new medicines for Peyronie’s disease
IRAS ID
334918
Contact name
Selim Cellek
Contact email
Sponsor organisation
Anglia Ruskin University
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Peyronie’s disease (PD) is characterised by a localised fibrotic plaque of the tunica albuginea (TA) of the penis. It can affect 3-10% of all men with the highest incidence in 60-70 age groups. The plaque formation can lead to pain, erectile dysfunction and irreversible penile deformity. There are currently no approved medical treatments for PD, only treatment option available is surgery.
Our research group has been working towards developing new medicines for PD for over 7 years. We have identified new molecular targets which we believe may lead to development of novel drugs for PD. The aim of this research is to further investigate these targets and to test chemical and biological compounds on these targets to develop new medicines.
During the surgery for PD, the fibrous plague is removed, part of which is used by the pathologist for diagnosis, and the remaining is discarded. During the surgery for penile cancer, some of the TA
which is noncancerous is removed as a part of the surgical procedure to make space for grafting. This tissue is also discarded. We are seeking approval to utilise these two types of tissues which are otherwise discarded. The specimens will be totally anonymised. There will no additional intervention or change to the surgical procedure/patient care.
The tissue samples will be utilised to obtain cells, proteins and other cellular components which will be used to test chemical and biological compounds in the laboratory. We are also seeking approval to share these material with other academic research institutes or pharmaceutical companies who will be supporting us towards developing new medicines for PD.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
23/WM/0265
Date of REC Opinion
5 Dec 2023
REC opinion
Further Information Favourable Opinion